(PSNL) Personalis, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PSNL) Personalis, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Personalis, Inc. 4P's Marketing Mix Analysis explains the company’s product offerings, pricing approach, distribution channels, and promotion tactics in a concise, actionable format; the page includes a real preview/sample of the analysis so you can review style and content before buying. Purchase the full version to receive the complete ready-to-use analysis.
Product
NeXT Platform cancer genomics
Personalis’ NeXT Platform is its core cancer genomics offering, built for detailed tumor profiling and immune microenvironment analysis. It uses sequencing and advanced data analysis to help researchers map tumor biology with high precision. The platform sits at the center of Personalis’ R&D business and supports its precision oncology focus.
ImmunoID Next tissue profiling
ImmunoID Next is Personalis, Inc.'s tissue-based tumor profiling service on the NeXT Platform, built to read tumor biology and the nearby immune environment from tissue samples. It supports oncology research and therapeutic development by helping teams link tumor signals to immune response.
As part of the 4P's mix, it is a high-value, research-focused product that targets drug developers and cancer labs needing deeper tissue insight than standard panel tests.
NeXT Liquid Biopsy plasma analysis
NeXT Liquid Biopsy analyzes plasma for cancer signals, extending Personalis testing to minimally invasive, low-input samples. Personalis, Inc. reported 2025 revenue of about $75.0 million, and this product supports repeat sampling for longitudinal monitoring and translational studies. That makes it a practical fit for research use where serial blood draws matter.
NeXT Personal and NeXT Dx Test
NeXT Personal is a liquid biopsy for tracking one patient’s tumor over time, while NeXT Dx Test is a genomic cancer profiling test that helps identify composite biomarkers and guide treatment. Together, they support clinical decisions, monitor disease response, and help physicians adjust care faster. For Personalis, Inc., this product pair sits at the core of precision oncology diagnostics.
- Personalized tumor tracking
- Genomic profiling for therapy guidance
- Supports monitoring and decision-making
NeXT SHERPA, NeXT NEOPS, and ACE platform
Personalis, Inc.'s NeXT SHERPA and NeXT NEOPS are neoantigen prediction tools, while the ACE platform also supports biomarker finding and new drug target selection. Together, 2 prediction tools plus 1 platform focus on precision oncology and immunotherapy discovery, where patient-specific tumor signals drive treatment design.
In 2025, this matters because oncology drug R&D remains one of the largest pharma spend pools, with global cancer drug sales staying above $200 billion.
- NeXT SHERPA: neoantigen prediction
- NeXT NEOPS: neoantigen prediction
- ACE: biomarkers and drug targets
Personalis: Precision Cancer Testing and Immune Discovery
Personalis, Inc.'s Product mix centers on NeXT Platform tests for tissue and liquid biopsy, plus immuno-oncology tools like SHERPA, NEOPS, and ACE. These products serve research and clinical oncology, with NeXT Personal and NeXT Dx supporting patient tracking and treatment guidance. In 2025, Personalis, Inc. reported about $75.0 million in revenue.
| Product | Use |
|---|---|
| NeXT Platform | Tumor profiling |
| NeXT Personal | Longitudinal tracking |
| SHERPA/NEOPS/ACE | Neoantigen and biomarker discovery |
What is included in the product
Detailed Word Document
A concise, company-specific deep dive into Personalis, Inc.’s Product, Price, Place, and Promotion strategies.
Editable Excel File
Condenses Personalis’s 4Ps into a quick, actionable view that helps teams spot gaps and align faster.
Reference Sources
Cites primary industry reports, government datasets, and peer-reviewed studies to speed due diligence and let investors trace every key claim back to its source.
Place
Global B2B operations
Personalis runs a global B2B model, selling advanced sequencing and cancer genomics services to hospitals, biotechs, and research groups, not retail buyers. The addressable oncology market is huge: GLOBOCAN 2022 counted about 20.0 million new cancer cases worldwide, which supports demand for precision-medicine testing. Its reach spans North America, Europe, and Asia, where research budgets and clinical trials drive orders.
Menlo Park, California headquarters
Personalis, Inc. is headquartered in Menlo Park, California, and in FY2025 this site anchored its corporate, scientific, and commercial work. The Bay Area base supports close collaboration with the U.S. life sciences ecosystem, including nearby research groups and biopharma partners. That location also helps Personalis recruit talent in one of the country’s deepest biotech labor pools.
Direct sales to biopharma
Biopharmaceutical companies are a core customer group for Personalis, and the Company sells through direct institutional relationships and project-based work. That fits complex genomic services that need deep scientific support, long sales cycles, and tailored study design. Direct selling also helps Personalis keep close contact with high-value biopharma accounts and adjust projects as research needs change.
Academic, nonprofit, and government channels
Personalis, Inc. sells to academic institutions, nonprofits, and government agencies through research partnerships, not retail channels. That fits clinical research and translational science workflows, where NIH’s FY2025 budget was about $47.0 billion and buying runs through grants, protocols, and multi-site studies.
- Academic and government labs are core buyers
- Sales happen via research collaboration
- Best fit: trial and translational workflows
- NIH FY2025: about $47.0 billion
Strategic partnerships and site collaborations
Personalis uses strategic partnerships with Mayo Clinic, MapKure, SpringWorks Therapeutics, and Moores Cancer Center to widen access to samples, studies, and validation settings. These 4 site ties help turn research into product use and new assay applications, so partnerships act as a key route to market.
- 4 named collaborators
- وسع sample and study access
- Supports validation and market entry
Personalis Leans on Bay Area Roots and Key Life-Science Partnerships
Place is mostly direct and partner-led, with sales centered on U.S. biotech, hospitals, and research groups from Menlo Park, California. That Bay Area base supports hiring and close work with life-science partners.
In FY2025, Personalis also leaned on academic and government research channels, including NIH-funded studies at about $47.0 billion.
Partnerships with Mayo Clinic, MapKure, SpringWorks Therapeutics, and Moores Cancer Center widen sample access and speed validation.
| Place factor | FY2025 data |
|---|---|
| HQ | Menlo Park, California |
| NIH budget | About $47.0 billion |
| Named partners | 4 |
What You See Is What You Get
Personalis, Inc. Reference Sources
The preview shown here is the actual Personalis, Inc. 4P's Marketing Mix document you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.
Promotion
Scientific partnership marketing
Personalis uses scientific partnership marketing through four collaborations: Mayo Clinic, MapKure, SpringWorks Therapeutics, and Moores Cancer Center. These ties boost technical credibility in oncology and immunogenomics, and they show how the platform works in real clinical and research settings. One clear signal: Personalis is not just selling a test, it is backing it with named medical partners.
Clinical and translational validation
Personalis promotes the NeXT Platform on one clear edge: it can read very small tissue and plasma samples, which matters when material is scarce. Clinical and translational validation in research and therapy development helps lower adoption risk and supports broader use in precision oncology workflows.
Precision oncology positioning
Personalis, Inc. positions precision oncology around novel cancer treatments and genetic research, with a clear focus on tumor profiling, biomarker discovery, neoantigen prediction, and patient monitoring. Its message speaks to drug developers and research teams that need data to guide trial design and treatment selection. In 2025, this kind of genomics-led workflow stays central as oncology R&D keeps shifting toward biomarker-driven care.
Institutional account outreach
Institutional account outreach at Personalis, Inc. targets biopharmaceutical companies, academic institutions, non-profits, and government entities, where buying is science-led and trust-heavy. Sales and technical teams work together through evaluation, validation, and adoption.
That fit matters because clinical and translational genomics deals often move through long review cycles, with multiple stakeholders and proof points before purchase.
- Targets science-first buyers.
- Relies on sales plus technical support.
- Built for relationship-led adoption.
Public-company communication
As a public Company, Personalis uses 10-K, 10-Q, and earnings updates to explain its platform and market opportunity. In FY2024, it reported about $77 million in revenue, and that public reporting helps customers, partners, and investors track progress and strategy.
- SEC filings build trust
- Revenue shows operating scale
- Updates reinforce market awareness
Personalis Builds Trust with Clinical Proof and Public Revenue Reporting
Personalis promotes its NeXT Platform through science-led partnerships and clinical validation, especially in oncology and immunogenomics. Its message focuses on low-input tissue and plasma testing, which helps when samples are scarce. Public SEC reporting also supports trust with buyers and investors.
| Promotion signal | Data point |
|---|---|
| Public reporting | FY2024 revenue about $77 million |
| Clinical proof | Mayo Clinic, MapKure, SpringWorks, Moores Cancer Center |
Price
Custom contract pricing
Personalis does not publish a consumer-style price list; pricing is set through negotiated institutional contracts for research and clinical testing. In FY2024, Personalis reported revenue of $71.4 million, showing this is a contract-led model, not a retail one.
This fits specialized genomic testing, where assay scope, sample volume, and turnaround time drive the final price.
Enterprise and study-based fees
Personalis, Inc. fees are usually set by study scope, sample count, and assay complexity, so pricing can rise fast for multi-omic oncology work. Large biopharma and research programs often use enterprise deals, which fit repeat testing and long trial timelines. That supports tailored pricing for high-value cancer studies, where budgets can run into millions of dollars.
Assay-specific pricing
Personalis uses assay-specific pricing because tissue profiling, liquid biopsy, and neoantigen prediction each need different lab steps, inputs, and data analysis.
That means price changes with the platform and the depth of analysis, so a simple tissue assay costs less than a custom multi-step research workflow.
This fits Personalis’ custom science model, where each customer buys a tailored service instead of a one-size-fits-all test.
Clinical test economics
Clinical test economics for Personalis, Inc. are tied to channel, payer mix, and test use, so NeXT Personal and NeXT Dx are priced case by case rather than as low-cost mass tests. That fits precision oncology, where one high-value result can guide treatment, and Personalis reported FY2025 revenue of about $100 million, showing the model is still small and specialized.
- Channel-driven pricing
- Billing depends on utilization
- Specialized, not mass-market
- Value linked to oncology decisions
Value-based positioning
Personalis, Inc. uses value-based pricing because buyers pay for sequencing plus clinical interpretation, not raw lab output. In oncology, that matters: a multi-gene test can cost far more than a basic assay, but the real value is faster, clearer treatment support.
This fits a premium model in a market where liquid biopsy and tumor profiling keep growing, and where each result can affect high-cost therapy choices. So the price reflects high technical content, bioinformatics, and decision-grade reporting.
- Prices track interpretation value, not just lab cost
- Oncology buyers need actionable insights
- Premium pricing fits complex genomic workflows
Personalis’ Tailored Pricing Drives Revenue Growth
Personalis, Inc. uses negotiated, value-based pricing, not public list prices, because each assay is tailored to sample type, workflow, and reporting depth. FY2025 revenue was about $100 million, up from $71.4 million in FY2024, which shows pricing is tied to contract wins and test volume. Higher-complexity oncology and multi-omic work command higher fees.
| Metric | FY2025 |
|---|---|
| Revenue | ~$100M |
| FY2024 revenue | $71.4M |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.